Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-titration study of CYT006-AngQb in mild to moderate essential hypertension
2007-007516-28Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Mar 2008
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CYT006-AngQb in essential hypertension (4 arms), sponsored by Cytos Biotechnology AG. Primary endpoints: Safety and tolerability, Pharmacodynamic effects and 1 more. Started Mar 2008; status: completed.
02
Drugs
CYT006-AngQb
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2007-007516-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007516-28.